XGEVA® (Denosumab): The FDA on June 13, 2013 approved the use of XGEVA® subcutaneous injection, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. XGEVA® is a product of Amgen Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
